Cyclooxygenase Inhibitors and Cardiovascular Risk—Reply

David Henry, Patricia McGettigan

Research output: Contribution to journalLetterResearchpeer-review

1 Citation (Scopus)

Abstract

In Reply: Dr Andersohn and colleagues suggest that the highest risks of cardiovascular events with celecoxib are seen in European study populations, where the CYP2C9*3 allele associated with slow metabolism of celecoxib (and by implication an increased risk of thrombosis) may occur with a frequency of as much as 16%. This is an interesting suggestion, but we can speculate that it may not be the most likely explanation for the heterogeneity observed in the study results.
Original languageEnglish
Pages (from-to)587-588
Number of pages2
JournalJournal of the American Medical Association
Volume297
Issue number6
DOIs
Publication statusPublished - 14 Feb 2007
Externally publishedYes

Fingerprint

Celecoxib
Cyclooxygenase Inhibitors
Thrombosis
Alleles
Population

Cite this

@article{0cbc5fcc14304c66a7c95cd167dedbda,
title = "Cyclooxygenase Inhibitors and Cardiovascular Risk—Reply",
abstract = "In Reply: Dr Andersohn and colleagues suggest that the highest risks of cardiovascular events with celecoxib are seen in European study populations, where the CYP2C9*3 allele associated with slow metabolism of celecoxib (and by implication an increased risk of thrombosis) may occur with a frequency of as much as 16{\%}. This is an interesting suggestion, but we can speculate that it may not be the most likely explanation for the heterogeneity observed in the study results.",
author = "David Henry and Patricia McGettigan",
year = "2007",
month = "2",
day = "14",
doi = "10.1001/jama.297.6.587",
language = "English",
volume = "297",
pages = "587--588",
journal = "Journal of the American Medical Association",
issn = "0098-7484",
publisher = "AMER MEDICAL ASSOC",
number = "6",

}

Cyclooxygenase Inhibitors and Cardiovascular Risk—Reply. / Henry, David; McGettigan, Patricia.

In: Journal of the American Medical Association, Vol. 297, No. 6, 14.02.2007, p. 587-588.

Research output: Contribution to journalLetterResearchpeer-review

TY - JOUR

T1 - Cyclooxygenase Inhibitors and Cardiovascular Risk—Reply

AU - Henry, David

AU - McGettigan, Patricia

PY - 2007/2/14

Y1 - 2007/2/14

N2 - In Reply: Dr Andersohn and colleagues suggest that the highest risks of cardiovascular events with celecoxib are seen in European study populations, where the CYP2C9*3 allele associated with slow metabolism of celecoxib (and by implication an increased risk of thrombosis) may occur with a frequency of as much as 16%. This is an interesting suggestion, but we can speculate that it may not be the most likely explanation for the heterogeneity observed in the study results.

AB - In Reply: Dr Andersohn and colleagues suggest that the highest risks of cardiovascular events with celecoxib are seen in European study populations, where the CYP2C9*3 allele associated with slow metabolism of celecoxib (and by implication an increased risk of thrombosis) may occur with a frequency of as much as 16%. This is an interesting suggestion, but we can speculate that it may not be the most likely explanation for the heterogeneity observed in the study results.

UR - http://www.scopus.com/inward/record.url?scp=33846953546&partnerID=8YFLogxK

U2 - 10.1001/jama.297.6.587

DO - 10.1001/jama.297.6.587

M3 - Letter

VL - 297

SP - 587

EP - 588

JO - Journal of the American Medical Association

JF - Journal of the American Medical Association

SN - 0098-7484

IS - 6

ER -